The purpose of this research is to study the medical and safety effects of a single dose of an investigational drug called psilocybin compared to a placebo in participants with depression.
Ecofibre Ltd & Southern Cross University have commenced Australia's largest clinical trial investigating CBD for sleep disturbances.
Study DMX-IB 201 is a Phase 1/2a study of ibogaine consisting of a randomized, double-blind, placebo-controlled proof of concept stage to demonstrate the efficacy, safety and tolerability of the selected dose in opioid-dependent patients who seek medically supervised opioid withdrawal.
The aim of the present study is to evaluate the safety, tolerability and efficacy of increasing doses of ibogaine in 12 alcoholic patients. Each patient will be hospitalized for 20 days and receive 3 increasing doses of ibogaine.
This phase-II RCT will dose 20 patients from the methadone maintenance program with ibogaine to establish efficacy and safety of ibogaine treatment.
Imperial College London will conduct a clinical trial with psilocybin-assisted therapy in the treatment of anorexia nervosa in adult women.
Clinical Trial – DMT-Assisted Therapy for Healthy Adults and Major Depressive Disorder (London/Manchester)
Small Pharma and Imperial College will conduct a clinical trial into the effects of DMT on Major Depressive Disorder. Both Healthy Volunteers and MDD patients will be included.
This open-label trial will investigate feasibility and efficacy of psilocybin-assisted psychotherapy for treatment-resistant depression.
This study will be a randomised controlled trial of repeated microdoses of LSD under schedules similar to those suggested in the grey literature. 80 healthy male volunteers will be randomised to receive repeated doses of either inactive placebo or LSD (10 µg oral) under double-blind conditions in a parallel groups design.
30 volunteers who have tried a hallucinogen will take a single oral dose of Ibogaine in a clinical setting and stay for 6 nights in the clinic.